Boxrud P D, Berliner L J
Department of Chemistry, Ohio State University, Columbus 43210-1173, USA.
J Protein Chem. 1996 Feb;15(2):231-42. doi: 10.1007/BF01887403.
The active site of the prothrombin activation intermediate meizothrombin(desF1) was probed using several fluorosulfonylphenyl spin labels specific for the active serine hydroxyl of serine proteases. The mobilities of the thrombin species inhibited with the nitroxide spin labels m-IV [4-(2,2,6,6-tetramethyl-piperidine-1-oxyl) -m-(fluorosulfonyl)benzamide] and m-V [3-(2,2,5,5-tetramethyl-pyrrolidine-1-oxyl) -m-(fluorosulfonyl)benzamide], which are sensitive to differences between alpha- and gamma-thrombin, were quite similar to that of alpha-thrombin. That is, no major conformational differences between meizothrombin(desF1) and alpha-thrombin were observed in this region of the extended active site. On the other hand, p-IV [4-(2,2,6,6-tetramethyl piperidine-1-oxyl)-p-(fluorosulfonyl)benzamide], p-V [3-(2,2,5,5-tetramethylpyrrolidine-1-oxyl) -p-(fluorosulfonyl)benzamide], and m-VII [N-[m- (fluorosulfonyl)phenyl]-4-N-(2,2,6,6-tetramethyl- piperidine-1-oxyl)urea], which probe an apolar binding region of bovine thrombin, exhibited large differences in mobility between alpha-thrombin and meizothrombin(desF1). The conformational consequences of indole binding to spin-labeled thrombin species demonstrated that both species also possess an indole-binding site. However, the nitroxide mobility changes upon indole binding to the spin-labeled protein derivative were somewhat different between the two thrombin species under study. In addition, the effects of the benzamidine binding were quite similar for each labeled protein. Thus is appears that, while both species posses a fully functional active site, the region in meizothrombin(desF1) probed by spin labels p-IV, p-V, and m-VII, which corresponds to the apolar binding region, differs in conformation from alpha-thrombin.
利用几种对丝氨酸蛋白酶活性丝氨酸羟基具有特异性的氟磺酰基苯基自旋标记物,对凝血酶原激活中间体中凝血酶(去F1)的活性位点进行了探测。用对α-凝血酶和γ-凝血酶之间差异敏感的氮氧化物自旋标记物m-IV [4-(2,2,6,6-四甲基哌啶-1-氧基)-间-(氟磺酰基)苯甲酰胺]和m-V [3-(2,2,5,5-四甲基吡咯烷-1-氧基)-间-(氟磺酰基)苯甲酰胺]抑制的凝血酶种类的迁移率,与α-凝血酶的迁移率非常相似。也就是说,在延伸活性位点的这个区域,中凝血酶(去F1)和α-凝血酶之间未观察到主要的构象差异。另一方面,探测牛凝血酶非极性结合区域的p-IV [4-(2,2,6,6-四甲基哌啶-1-氧基)-对-(氟磺酰基)苯甲酰胺]、p-V [3-(2,2,5,5-四甲基吡咯烷-1-氧基)-对-(氟磺酰基)苯甲酰胺]和m-VII [N-[间-(氟磺酰基)苯基]-4-N-(2,2,6,6-四甲基哌啶-1-氧基)脲],在α-凝血酶和中凝血酶(去F1)之间的迁移率表现出很大差异。吲哚与自旋标记的凝血酶种类结合的构象结果表明,这两种种类也都具有吲哚结合位点。然而,在所研究的两种凝血酶种类中,吲哚与自旋标记的蛋白质衍生物结合后,氮氧化物迁移率的变化略有不同。此外,苯甲脒结合对每种标记蛋白质的影响非常相似。因此,似乎虽然这两种种类都具有功能完全的活性位点,但自旋标记物p-IV、p-V和m-VII探测的中凝血酶(去F1)区域,即对应于非极性结合区域,其构象与α-凝血酶不同。